Accuray Incorporated (ARAY) News

Accuray Incorporated (ARAY): $1.92

-0.04 (-2.04%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter ARAY News Items

ARAY News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ARAY News Highlights

  • For ARAY, its 30 day story count is now at 18.
  • Over the past 19 days, the trend for ARAY's stories per day has been choppy and unclear. It has oscillated between 1 and 8.
  • The most mentioned tickers in articles about ARAY are LUNG, DECK and TT.

Latest ARAY News From Around the Web

Below are the latest news stories about Accuray Inc that investors may wish to consider to help them evaluate ARAY as an investment opportunity.

Largest Hospital in Queensland, Australia Acquires Multiple Accuray Radixact® Systems with the ClearRT™ Helical Fan-Beam kVCT Imaging and Synchrony® Technologies

Accuray Incorporated (NASDAQ: ARAY) announced today that Royal Brisbane and Women's Hospital (RBWH), the largest medical facility in Queensland, Australia, has selected two Radixact Systems with ClearRT™ helical fan-beam kVCT imaging and Synchrony® artificial intelligence (AI)-driven four-dimensional (4D) dynamic delivery technology to expand access to potentially life-saving radiotherapy treatments to more patients. The Radixact Systems will replace existing, older TomoTherapy® Systems and in c

Yahoo | February 14, 2022

Accuray rises 10% as TomoTherapy preserves heart/lung function in breast cancer patients

Accuray (ARAY) said data from a phase 3 trial, dubbed TomoBreast, suggested that post-surgery hypofractionated radiotherapy delivered with the TomoTherapy System is superior to…

Seeking Alpha | February 10, 2022

Accuray's TomoTherapy Superior To Conventional Radiotherapy In Preserving Heart, Lung Functioning

Accuray Incorporated (NASDAQ: ARAY) announced data from a Phase 3 TomoBreast trial of TomoTherapy System (TT) versus conventional post-surgery radiotherapy (CR) for breast cancer designed to test the hypothesis that TT might reduce lung-heart toxicity. An analysis of patient-reported outcomes showed 10-year survival free of heart and lung deterioration was 84.5% with TomoTherapy delivered radiotherapy, a significant improvement above the 66.9% achieved with conventional radiotherapy. The TomoThe

Yahoo | February 10, 2022

Accuray TomoTherapy® Helical Radiotherapy System Helps Preserve Breast Cancer Patients' Long-term Heart and Lung Functionality

Accuray Incorporated (NASDAQ: ARAY) announced today that data from a phase III, randomized controlled trial, TomoBreast, indicate post-surgery hypofractionated radiotherapy delivered with the TomoTherapy® System is superior to conventional radiotherapy in preserving long-term heart and lung functioning in women with early breast cancer. An analysis of patient reported outcomes showed 10-year survival free of heart and lung deterioration was 84.5% with TomoTherapy delivered radiotherapy - a signi

Yahoo | February 10, 2022

Accuray to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 15-17, 2022. As part of the conference, the company's management team will participate in a virtual fireside chat on Wednesday, February 16, 2022 at 3:30 pm EST / 12:30 pm PST.

Yahoo | February 7, 2022

Shareholders in Accuray (NASDAQ:ARAY) have lost 37%, as stock drops 17% this past week

Ideally, your overall portfolio should beat the market average. But the main game is to find enough winners to more...

Yahoo | January 28, 2022

Accuray Incorporated (ARAY) CEO Joshua Levine on Q2 2022 Earnings Call Transcript

Accuray Incorporated (ARAY) Q2 2022 Earnings Conference Call Jan 26, 2022 04:30 PM ET Company Participants Ken Mobeck - VP, Finance and IR Joshua Levine - President and CEO Suzanne Winter - President Brandon Green - Interim CFO Conference Call Participants Michael Cox - Lake Street Capital Markets Marie Thibault...

SA Transcripts on Seeking Alpha | January 27, 2022

Accuray (ARAY) Q2 Earnings Miss Estimates, Margins Down

Accuray (ARAY) registers growth in Products revenues during fiscal Q2, thereby partly driving its overall top line.

Yahoo | January 27, 2022

New Strong Sell Stocks for January 27th

ARAY, XAIR, and EMKR have been added to the Zacks Rank #5 (Strong Sell) List on January 27, 2022

Yahoo | January 27, 2022

Accuray (ARAY) Q2 2022 Earnings Call Transcript

Welcome to Accuray's conference call to review financial results for the second quarter of fiscal year 2022, which ended December 31, 2021. Joining us on today's call are Josh Levine, Accuray's chief executive officer; Suzanne Winter, Accuray's president; and Brandy Green, Accuray's interim chief financial officer.

Yahoo | January 27, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5434 seconds.